Bringing transformative therapies to rare disease patients in China and beyond
CANbridge Pharmaceuticals (HKEX: 1228) is a global biopharmaceutical company with a foundation in China, committed to the research, development, and commercialization of rare disease therapeutics. The company has a differentiated drug portfolio with 3 approved drugs and a pipeline of 7 clinical assets, focusing on prevalent rare disease indications including mucopolysaccharidosis, Gaucher disease, and other rare genetic disorders. CANbridge operates a Next-Generation Innovation and Process Development Facility developing novel gene therapies, and partners globally with leading biotech and pharma companies to bring treatments to patients in China and worldwide.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2020
Feb 2020
May 2017
Oct 2015
Dec 2014
Create a free account to see which investors have funded this company.
Create Free Account
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Global biosimulation software and services company accelerating drug development for 2,000+ bioph...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
